ClinicalTrials.gg
CompletedNCT00569803Updated Sep 22, 2016Results posted

Subcutaneous Pharmacokinetics of Belatacept

A Phase 1 interventional study of belatacept and Placebo in Transplantation, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

02

Conditions studied

  • Transplantation
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 18 to 65 years old
  • Subjects must weigh less than or equal to 100 kg

Exclusion criteria

Exclusion Criteria:

  • Inability to tolerate injections or IV infusions
  • disorders
  • TB
  • herpes
  • bacterial or viral infection
  • history of cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
153 participants (actual)

Study arms

  • Active comparator
    Belatacept 50 mg Subcutaneous Injection

    Belatacept 50 mg subcutaneous (SC) injection

    Drug: belatacept

  • Active comparator
    Belatacept 100 mg Subcutaneous Injection

    Belatacept 100 mg SC injection

    Drug: belatacept

  • Active comparator
    Belatacept 125 mg Subcutaneous Injection

    Belatacept 125 mg SC injection

    Drug: belatacept

  • Active comparator
    Belatacept 150 mg Subcutaneous Injections

    2 SC injections of 75 mg Belatacept

    Drug: belatacept

  • Active comparator
    Belatacept 200 mg Subcutaneous Injections

    2 SC injections of 100 mg Belatacept

    Drug: belatacept

  • Active comparator
    Belatacept 250 mg Subcutaneous Injections

    2 SC injections of 125 mg Belatacept

    Drug: belatacept

  • Active comparator
    Belatacept 125 mg Intravenous Infusion

    125 mg Belatacept intravenous (IV) injection

    Drug: belatacept

  • Placebo comparator
    Placebo

    SC injection of placebo solution

    Drug: Placebo

Interventions

  • single dose, 116 days

  • DrugPlacebo

    Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Belatacept

    Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  2. Time of Maximum Observed Serum Concentration (Tmax) of Belatacept

    Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  3. Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept

    Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL).

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  4. Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept

    Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL)

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  5. Serum Half-life (T-HALF) of Belatacept

    Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  6. Apparent Total Body Clearance (CLT/F) of SC Belatacept

    Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  7. Total Body Clearance (CLT) of IV Belatacept

    Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  8. Volume of Distribution at Steady State (VSS) for IV Belatacept

    Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  9. Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept

    Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

Secondary outcomes

  1. Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption

    AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug\*h/mL). AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration. AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.

    Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116

  2. Number of Participants With Vital Sign Abnormalities

    Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.

    Time frame: 1 day pre-dose, Days 1, 2, 5, 14, 28, 42, 86 and 116

  3. Number of Participants With Injection Site Reactions

    Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.

    Time frame: 0.5, 2, 6 and 24 hours post-dose, Days 3, 4, 5, 6, 7, 8, 14, 21 and 116

  4. Number of Participants With Physical Examination Abnormalities

    All clinically significant deviations from normal physical examinations were reported.

    Time frame: Days 1, 2, 5, 14, 28, 42, 86, 116

  5. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.

    Time frame: Days 1 and 116

  6. Number of Participants With Marked Hematology Laboratory Abnormalities

    LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): \<0.85\*Pre-Rx. Hematocrit (%): \<0.85\*Pre-Rx. Platelet Count (\*10\^9 cells per liter:c/L): \<0.85\*LLN or \>1.5\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx). Leukocytes (\*10\^3 cells per microliter: c/uL): \<0.9\*LLN, \>1.2\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx or \>ULN, if Pre-Rx\>ULN, use \>1.15\*Pre-Rx or \<LLN) Neutrophils+Bands (\*10\^3 c/uL): \<=1.500. Lymphocytes (\*10\^3 c/uL): \<0.750 or \>7.500. Monocytes (\*10\^3 c/uL): \>2.000. Basophils (\*10\^3 c/uL): \>0.400. Eosinophils (\*10\^3 c/uL): \>0.750.

    Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116

  7. Number of Participants With Marked Serum Chemistry Abnormalities

    LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Blood Urea Nitrogen (mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.2\*Pre-Rx). Creatinine (mg/dL): \>1.33\*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): \<0.95\*LLN, \>1.05\*ULN (if Pre-Rx\<LLN: \<0.95\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.05\*Pre-Rx, \<LLN). Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Phosphorus (mg/dL): \<0.85\*LLN, \>1.25\*ULN (if Pre-Rx\<LLN, \<0.85\*Pre-Rx, \>ULN. if Pre-Rx\>ULN: \>1.25\*Pre-Rx, \<LLN).

    Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116

  8. Number of Participants With Marked Laboratory Abnormalities

    LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose (mg/dL): \<0.8\*LLN, \>1.5\*ULN (if Pre-Rx\<LLN: \<0.8\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>2.0\*Pre-Rx, \<LLN). Protein (grams per deciliter: g/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Albumin (g/dL): \<0.9\*LLN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx). Uric Acid (mg.dL): \>1.2\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Lactate Dehydrogenase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx)

    Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116

  9. Number of Participants With Positive Immunogenicity to Belatacept

    The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.

    Time frame: Days 1, 14, 28, 42, 56, 86, 116

07

Results

Posted Aug 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Started555655106
Completed455555105
Not completed10010001
Withdrew: Lost to follow-up10000000
Withdrew: Injection syringe leaked during dosing00010000
Withdrew: Withdrawal by subject00000001

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax) of Belatacept

Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Concentration (Cmax) of Belatacept
ug/mLBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Maximum Observed Serum Concentration (Cmax) of Belatacept3.9 ± 306.2 ± 348.5 ± 5011.1 ± 1914.5 ± 1614.5 ± 1842.4 ± 16
PrimaryTime of Maximum Observed Serum Concentration (Tmax) of Belatacept

Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Median · hours
Time of Maximum Observed Serum Concentration (Tmax) of Belatacept
hoursBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Time of Maximum Observed Serum Concentration (Tmax) of Belatacept84 (36 to 96)60 (48 to 120)96 (48 to 144)60 (36 to 96)60 (24 to 84)72 (60 to 96)0.5 (0.2 to 2.0)
PrimaryAdjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept

Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL).

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · ug*h/mL
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept
ug*h/mLBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept2587 (2132 to 3139)1848 (1523 to 2242)2371 (1954 to 2876)2703 (2228 to 3280)2650 (2184 to 3215)2193 (1807 to 2660)3023 (2637 to 3466)
Statistical analysis
  • Belatacept 50 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.86 · 90% CI 0.68 to 1.08Ratio of Geometric Means: 50mg SC over 125mg IV
  • Belatacept 100 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.61 · 90% CI 0.48 to 0.77Ratio of Geometric Means: 100mg SC over 125mg IV
  • Belatacept 125 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.78 · 90% CI 0.62 to 0.99Ratio of Geometric Means: 125mg SC over 125mg IV
  • Belatacept 150 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.89 · 90% CI 0.71 to 1.13Ratio of Geometric Means: 150mg SC over 125mg IV
  • Belatacept 200 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.88 · 90% CI 0.69 to 1.11Ratio of Geometric Means: 200mg SC over 125mg IV
  • Belatacept 250 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.73 · 90% CI 0.57 to 0.92Ratio of Geometric Means: 250mg SC over 125mg IV
PrimaryAdjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept

Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL)

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · ug*h/mL
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept
ug*h/mLBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept2639 (2172 to 3205)1851 (1524 to 2248)2380 (1959 to 2891)2719 (2238 to 3303)2666 (2194 to 3238)2201 (1812 to 2673)3031 (2642 to 3478)
Statistical analysis
  • Belatacept 50 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.87 · 90% CI 0.69 to 1.10Ratio of Geometric Means: 50mg SC over 125mg IV
  • Belatacept 100 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.61 · 90% CI 0.48 to 0.77Ratio of Geometric Means: 100mg SC over 125mg IV
  • Belatacept 125 mg Subcutaneous Injection vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.79 · 90% CI 0.62 to 1.00Ratio of Geometric Means: 125mg SC over 125mg IV
  • Belatacept 150 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.90 · 90% CI 0.71 to 1.14Ratio of Geometric Means: 150mg SC over 125mg IV
  • Belatacept 200 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.88 · 90% CI 0.69 to 1.12Ratio of Geometric Means: 200mg SC over 125mg IV
  • Belatacept 250 mg Subcutaneous Injections vs Belatacept 125 mg Intravenous Infusion · Ratio of geometric means: 0.73 · 90% CI 0.57 to 0.92Ratio of Geometric Means: 250mg SC over 125mg IV
PrimarySerum Half-life (T-HALF) of Belatacept

Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Mean · hours
Serum Half-life (T-HALF) of Belatacept
hoursBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Serum Half-life (T-HALF) of Belatacept112 ± 25.7100 ± 10.1135 ± 47.6158 ± 46.9161 ± 45.3150 ± 43.6130 ± 27.6
PrimaryApparent Total Body Clearance (CLT/F) of SC Belatacept

Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · mL/h
Apparent Total Body Clearance (CLT/F) of SC Belatacept
mL/hBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous Injections
Apparent Total Body Clearance (CLT/F) of SC Belatacept47.4 ± 2767.5 ± 3452.5 ± 3146.0 ± 2646.9 ± 2156.8 ± 20
PrimaryTotal Body Clearance (CLT) of IV Belatacept

Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · mL/h
Total Body Clearance (CLT) of IV Belatacept
mL/hBelatacept 125 mg Intravenous Infusion
Total Body Clearance (CLT) of IV Belatacept41.2 ± 21
PrimaryVolume of Distribution at Steady State (VSS) for IV Belatacept

Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Mean · Liters
Volume of Distribution at Steady State (VSS) for IV Belatacept
LitersBelatacept 125 mg Intravenous Infusion
Volume of Distribution at Steady State (VSS) for IV Belatacept7.3 ± 1.27
PrimaryApparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept

Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept
LitersBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous Injections
Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept10.79 ± 31.0215.30 ± 28.7914.12 ± 36.6312.75 ± 14.2013.34 ± 13.7715.82 ± 11.92
SecondaryEffect of Number of Injection Sites on Subcutaneous Belatacept Absorption

AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug\*h/mL). AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration. AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.

Time frame:
Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Reported as:
Geometric mean · ug*h/mL
Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption
ug*h/mL1 Injection Site2 Injection Sites
AUC(0-T)898 (794 to 1017)1002 (885 to 1134)
AUC(INF)906 (799 to 1027)1007 (888 to 1142)
Statistical analysis
  • 1 Injection Site vs 2 Injection Sites · Ratio of geometric means: 0.90 · 90% CI 0.75 to 1.07AUC(0-T) Ratio of Geometric Means: 1 injection site over 2 injection sites
  • 1 Injection Site vs 2 Injection Sites · Ratio of geometric means: 0.90 · 90% CI 0.75 to 1.07AUC(INF) Ratio of Geometric Means: 1 injection site over 2 injection sites
SecondaryNumber of Participants With Vital Sign Abnormalities

Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.

Time frame:
1 day pre-dose, Days 1, 2, 5, 14, 28, 42, 86 and 116
Reported as:
Number · participants
Number of Participants With Vital Sign Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Number of Participants With Vital Sign Abnormalities00000000
SecondaryNumber of Participants With Injection Site Reactions

Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.

Time frame:
0.5, 2, 6 and 24 hours post-dose, Days 3, 4, 5, 6, 7, 8, 14, 21 and 116
Reported as:
Number · participants
Number of Participants With Injection Site Reactions
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
mild reaction01101000
moderate reaction00001000
severe reaction00000000
SecondaryNumber of Participants With Physical Examination Abnormalities

All clinically significant deviations from normal physical examinations were reported.

Time frame:
Days 1, 2, 5, 14, 28, 42, 86, 116
Reported as:
Number · participants
Number of Participants With Physical Examination Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Number of Participants With Physical Examination Abnormalities00000000
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.

Time frame:
Days 1 and 116
Reported as:
Number · participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Screening (Day 1)00201010
Study Discharge (Day 116)00201010
SecondaryNumber of Participants With Marked Hematology Laboratory Abnormalities

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): \<0.85\*Pre-Rx. Hematocrit (%): \<0.85\*Pre-Rx. Platelet Count (\*10\^9 cells per liter:c/L): \<0.85\*LLN or \>1.5\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx). Leukocytes (\*10\^3 cells per microliter: c/uL): \<0.9\*LLN, \>1.2\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx or \>ULN, if Pre-Rx\>ULN, use \>1.15\*Pre-Rx or \<LLN) Neutrophils+Bands (\*10\^3 c/uL): \<=1.500. Lymphocytes (\*10\^3 c/uL): \<0.750 or \>7.500. Monocytes (\*10\^3 c/uL): \>2.000. Basophils (\*10\^3 c/uL): \>0.400. Eosinophils (\*10\^3 c/uL): \>0.750.

Time frame:
Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Reported as:
Number · participants
Number of Participants With Marked Hematology Laboratory Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Hemoglobin00000000
Hematocrit00000000
Platelet Count00000000
Leukocytes00010000
Neutrophils + Bands (absolute)00021000
Lymphocytes (absolute)00001000
Monocytes (absolute)00000000
Basophils (absolute)00000000
Eosinophils (absolute)00000000
SecondaryNumber of Participants With Marked Serum Chemistry Abnormalities

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Blood Urea Nitrogen (mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.2\*Pre-Rx). Creatinine (mg/dL): \>1.33\*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): \<0.95\*LLN, \>1.05\*ULN (if Pre-Rx\<LLN: \<0.95\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.05\*Pre-Rx, \<LLN). Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Phosphorus (mg/dL): \<0.85\*LLN, \>1.25\*ULN (if Pre-Rx\<LLN, \<0.85\*Pre-Rx, \>ULN. if Pre-Rx\>ULN: \>1.25\*Pre-Rx, \<LLN).

Time frame:
Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Reported as:
Number · participants
Number of Participants With Marked Serum Chemistry Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Alkaline Phosphatase00000000
Aspartate Aminotransferase00000011
Alanine Aminotransferase00000010
Bilirubin00001100
Blood Urea Nitrogen00000001
Creatinine00000000
Sodium, Serum00000000
Potassium, Serum00001000
Chloride, Serum00000000
Calcium, Total00000000
Phosphorus, Inorganic10000000
SecondaryNumber of Participants With Marked Laboratory Abnormalities

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose (mg/dL): \<0.8\*LLN, \>1.5\*ULN (if Pre-Rx\<LLN: \<0.8\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>2.0\*Pre-Rx, \<LLN). Protein (grams per deciliter: g/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Albumin (g/dL): \<0.9\*LLN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx). Uric Acid (mg.dL): \>1.2\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Lactate Dehydrogenase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx)

Time frame:
Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlacebo
Glucose, Fasting Serum11000000
Protein, Total00000000
Albumin00000000
Uric Acid00000000
Lactate Dehydrogenase00000000
SecondaryNumber of Participants With Positive Immunogenicity to Belatacept

The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.

Time frame:
Days 1, 14, 28, 42, 56, 86, 116
Reported as:
Number · participants
Number of Participants With Positive Immunogenicity to Belatacept
participantsBelatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous Infusion
Number of Participants With Positive Immunogenicity to Belatacept45555510

Adverse events

Collected over From Day 1 until 30 days post discontinuation of dosing, up to August 2008 (approximately 8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belatacept 50mg SC—0/5 (0%)2/5 (40%)
Belatacept 100mg SC—0/5 (0%)3/5 (60%)
Belatacept 125mg SC—0/5 (0%)3/5 (60%)
Belatacept 150mg SC—0/6 (0%)4/6 (66.7%)
Belatacept 200mg SC—0/5 (0%)2/5 (40%)
Belatacept 250mg SC—0/5 (0%)2/5 (40%)
Belatacept 125mg IV—0/10 (0%)7/10 (70%)
PLACEBO—0/6 (0%)1/6 (16.7%)
All Belatacept—0/41 (0%)23/41 (56.1%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventBelatacept 50mg SCBelatacept 100mg SCBelatacept 125mg SCBelatacept 150mg SCBelatacept 200mg SCBelatacept 250mg SCBelatacept 125mg IVPLACEBOAll Belatacept
HeadacheNervous system disorders0/52/52/50/61/50/53/100/68/41
NauseaGastrointestinal disorders0/50/51/52/60/50/50/100/63/41
Feeling hotGeneral disorders0/50/50/52/60/50/50/100/62/41
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/51/51/51/60/51/53/100/68/41
MyalgiaMusculoskeletal and connective tissue disorders0/50/51/50/60/50/51/100/62/41
Abdominal painGastrointestinal disorders0/50/50/50/61/50/50/100/61/41
Arthropod stingInjury, poisoning and procedural complications0/51/50/50/60/50/50/100/61/41
Injection site inflammationGeneral disorders0/50/51/50/60/50/50/100/61/41
Urinary tract infectionInfections and infestations0/51/50/50/60/50/50/100/61/41
Pain in extremityMusculoskeletal and connective tissue disorders1/50/50/50/60/50/50/100/61/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Belatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlaceboTotal
Mean30 ± 1127 ± 1228 ± 1234 ± 1831 ± 1131 ± 1032 ± 1627 ± 630 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Belatacept 50 mg Subcutaneous InjectionBelatacept 100 mg Subcutaneous InjectionBelatacept 125 mg Subcutaneous InjectionBelatacept 150 mg Subcutaneous InjectionsBelatacept 200 mg Subcutaneous InjectionsBelatacept 250 mg Subcutaneous InjectionsBelatacept 125 mg Intravenous InfusionPlaceboTotal
Female4222322421
Male1334238226
08

Study locations

1 site
  • Ppd Development
    Austin, Texas 78744, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 8 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2007
First posted
Dec 7, 2007
Start
Dec 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Aug 15, 2016
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00569803
Responsible party
Sponsor
First posted
Dec 7, 2007
Start date
Dec 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Aug 15, 2016
Last update
Sep 22, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion